EC approves Teva's Lonquex

The European Commission approved Lonquex lipegfilgrastim from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) to prevent chemotherapy-induced neutropenia. The glyco-pegylated recombinant human G-CSF ( CSF3) is approved to reduce the duration of neutropenia and the incidence of febrile neutropenia in adults treated with cytotoxic chemotherapy for malignancy, excluding chronic myelogenous leukemia (CML) and myelodysplastic syndromes (MDS). Teva gained Lonquex through its 2010 acquisition of ratiopharm GmbH. ...